"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." New England Journal of Medicine , 2025 (ATTAIN-1 trial) Eli Lilly press release: ATTAIN-2 Phase 3 topline results
To view or add a comment, sign in Researchers found that follistatin (FST) protects against atherosclerosis by increasing fat burning, improving mitochondrial function, reducing inflammation, stabilizing arterial plaques, and enhancing lipid metabolism, making it a promising therapeutic target for cardiovascular disease
We performed a stepwise linear regression analysis for each group separately, and for all 41 participants, with age, sex, BMI, HbA 1c , and difference of temperature between cold and hot OGTTs as independent variables
Professional guidance ensures proper administration techniques are followed
Ultimately, both options are effective for managing weight and controlling blood sugar